G

GE Healthcare

Imaging, monitoring, and healthcare IT solutions

Project Management Team Leader - Turnkey Operations

Full-TimeUpdated
No salary listed
Expert
Bachelor's
Gurugram, Haryana, India
In PersonRegular travel to project sites is required.
Architecture & Civil EngineeringConstruction Management

About the job

Requirements
  • A bachelor's degree in Civil Engineering, Construction Management, or a related field is required.
  • At least 15 years of project management experience in the construction industry is required, preferably in healthcare facilities or large technical installations.
  • Strong knowledge of local construction laws, permitting, and regulatory compliance is required.
  • Experience in contract drafting, negotiation, and management is required.
  • Expertise in budgeting, forecasting, and cost control is required.
  • Willingness to travel regularly to project sites is required.
Responsibilities
  • Lead end-to-end delivery of turnkey construction projects, from scoping and budgeting to execution and handover.
  • Act as the primary customer and contractor liaison, ensuring compliance with local laws, building codes, and GE HealthCare standards.
  • Prepare, review, and manage contracts while driving cost control, budgeting, and risk management.
  • Select, onboard, and oversee contractors, architects, and suppliers, ensuring safe and high-quality project execution.
  • Conduct site inspections, resolve escalations, and ensure adherence to contractual, environmental, health and safety, and quality requirements.
  • Provide accurate project reporting, financial forecasts, and insights to support business planning.
  • Capture lessons learned and contribute to the standardization of construction project processes and tools.
  • Coach and develop senior talent.
Desired Qualifications
  • Project management experience in healthcare facilities or large technical installations is preferred.
  • Strong oral and written communication skills and proper documentation are desired.

About the company

GE Healthcare Systems provides medical technologies and digital infrastructure to improve diagnosis, treatment, and monitoring of patients. Its products include imaging systems, mobile diagnostic devices, patient monitoring tools, and healthcare IT software that work together as hardware, software, and services to support hospitals, clinics, and researchers. The company differentiates itself with a large, integrated ecosystem, strong focus on AI analytics, and a global service network backed by substantial R&D investment. Its goal is to improve patient outcomes and the efficiency of healthcare delivery by enabling accurate diagnoses, effective treatments, and scaled operations.

Company Size

1-10

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

1892

Get referred to GE Healthcare

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 orders rose 11% and backlog reached a record $23.9 billion.
  • CareIntellect for Operations launched September 2026 with Duke Health and Queen's Health Systems.
  • CE mark and FDA progress for Photonova Spectra expand 2026-2027 commercial momentum.

What critics are saying

  • FDA logged multiple 2026 Class 2 recalls, including AW Server and telemetry systems.
  • Patient Care Solutions remained weak in Q2 2026; management is reviewing a sale.
  • SOFIE closes only after 2027 regulatory approvals; PET supply integration can slip badly.

What makes GE Healthcare unique

  • GE HealthCare combines imaging hardware, radiopharmaceuticals, and workflow software across hospitals.
  • Photonova Spectra and Vivid 2026 show premium innovation plus AI-enabled clinical automation.
  • SOFIE's 21 cyclotrons extend GE HealthCare into radiotracer manufacturing, not just scanners.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Tuition Reimbursement
  • Relocation Assistance

Company News

Yahoo Finance
Oct 29th, 2026
GE HealthCare raises 2026 guidance after Q3 revenue climbs 6.2% to $5.5B

GE HealthCare raised its full-year outlook after third-quarter revenue rose 6.2% organically to $5.5 billion. Adjusted earnings per share climbed 25.1% to $1.34, and free cash flow reached $793 million. The company now expects about 4% organic revenue growth, adjusted earnings per share of $4.95 to $5.05, and free cash flow above $1.6 billion. Adjusted EBIT margin rose to 16.6%, and the dividend increased 14%. Pharmaceutical Diagnostics led growth, with organic revenue up 13.8% on contrast media and radiopharmaceuticals. The planned SOFIE Biosciences acquisition would add roughly 1% to annualised revenue and strengthen radiopharmaceutical supply. The backlog stood at $23.7 billion, up 12% from a year earlier.

Yahoo Finance
Oct 23rd, 2026
Cash-rich stocks: Clean Harbors worth watching, UPS and GE HealthCare best avoided

StockStory has named one cash-generating stock worth a closer look and two it would avoid, arguing that strong cash flow does not always mean strong returns. Clean Harbors (NYSE:CLH) is the pick. Its revenue grew 13.5% a year over five years, and earnings per share rose 21.6% a year, helped by share buybacks. Its free cash flow margin is 8.8%, up 5.9 percentage points over five years. The shares trade at $320.91, or 30.7x forward earnings. StockStory would steer clear of United Parcel Service (NYSE:UPS) and GE HealthCare (NASDAQ:GEHC). UPS sales were flat over five years while earnings per share fell 8.4% a year. GE HealthCare faces projected sales growth of 4.4% and a 1.7-point drop in adjusted operating margin.

Associated Press
Oct 20th, 2026
GE HealthCare launches five-institution global trial of StarGuide GX theranostics SPECT/CT system

GE HealthCare has launched a clinical evaluation program for StarGuide GX, its next-generation digital 4D SPECT/CT system. Five institutions across three continents will take part. They are Hadassah Medical Center and Rambam Health Care Campus in Israel, Mayo Clinic in the US, Oncopole Claudius Regaud in France, and Peking University First Hospital in China. Each will assess image quality, quantitative performance, dynamic imaging, and workflow, and give feedback to guide the system's development. StarGuide GX uses dual-sided cadmium zinc telluride detectors and a dual-collimator design meant to remove manual collimator changes. It also uses NVIDIA RTX accelerated computing for image reconstruction. The system received CE Mark in November 2025 and is on sale in select EU states. Its US Food and Drug Administration 510(k) clearance is pending.

Yahoo Finance
Oct 19th, 2026
GE HealthCare launches LOGIQ Focus ultrasound with AI tools, 26% faster scans

GE HealthCare has launched LOGIQ Focus, a new general imaging ultrasound system in its LOGIQ family. The company announced the product in Chicago on October 19, 2026. The system runs on cSound Architecture and pairs high-definition imaging with AI-enabled tools. One of them, Auto Preset Assistant, detects the anatomy being scanned and activates the matching preset, saving up to five clicks per exam. In a third-party study, 90% of participants rated its image quality as excellent. The system was 26% faster than the predicate system. LOGIQ Focus is 510(k) cleared and CE Marked. GE HealthCare expects it and several other new products to add 1% to 2% to revenue growth, following more than $5 billion in innovation investment since 2023.

Business Wire
Oct 5th, 2026
GE HealthCare to acquire SOFIE Biosciences for $945M to expand US radiopharmaceutical supply

GE HealthCare has agreed to acquire SOFIE Biosciences, a US-based contract manufacturer of PET radiopharmaceuticals, for $945 million in cash. The deal with seller Trilantic North America is expected to close in the first half of 2027, subject to regulatory approvals. SOFIE Biosciences operates 15 contract manufacturing sites with 21 cyclotrons across the US, plus a theranostics-focused development and manufacturing facility. The acquisition establishes GE HealthCare's presence in the time-critical "final mile" of US PET radiopharmaceutical supply. The PET radiopharmaceutical market is expanding rapidly with approximately 20 PET radiotracers and over 30 radiotherapeutics currently under development. SOFIE Biosciences' portfolio includes a Phase III FAPI asset for which GE HealthCare already holds non-US rights. GE HealthCare estimates the transaction will be accretive to revenue growth, earnings margin, and earnings per share in the first full year of ownership.